Halogenated DNA ligand radiosensitizers for cancer therapy

Details Halogenated DNA ligand radiosensitizers for cancer therapy Halogenated DNA ligand radiosensitizers for cancer therapy

1995-05-15

1997-06-24

Kight, John

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514 79, 514 81, 544364, 536 187, A01N 5700, A61K 31675

Patent

active

056417640

ABSTRACT:
A radiosensitizer for use in radiotherapy comprises a halogenated DNA ligand. The susceptibility of DNA to radiation damage is enhanced by causing or allowing the halogenated DNA ligand to bind to the DNA before subjecting the DNA or the locus thereof to ionizing or ultraviolet radiation. Radiation damage in DNA is also induced by causing or allowing a halogenated DNA ligand to bind to DNA and irradiating the DNA and said bound ligand or the locus thereof with ionizing or ultraviolet radiation.

REFERENCES:
patent: 4415588 (1983-11-01), Cavazza
patent: 4415589 (1983-11-01), Cavazza
patent: 4464393 (1984-08-01), Cavazza
patent: 4663352 (1987-05-01), Onofrj
patent: 4751242 (1988-06-01), Calvani et al.
patent: 5096694 (1992-03-01), Quivy et al.
Murray et al, Sequence Specificity of .sup.125 I-labelled Hoechst 33258 Damage in Six Closely Related DNA Sequences, J. Mol. Biol., 203:63-73 (1988).
Murray et al, Sequence Specificity of .sup.125 I-labelled Hoechst 33258 in Intact Human Cells, J. Mol. Biol., 201:437-442 (1988).
Russell et al, In Vitro and in Vivo Radiation Sensitization by the Halogenated Pyrimidine 5-Chloro-2'-deoxycytidine, Cancer Res., 46:2883-2887 (1986).
Marcus, Clinical Photodynamic Therapy: The Continuing Evolution, pp. 219-268.
Teng et al, The Molecular Structure of the Complex of Hoechst 33258 and the DNA Dodecamer d(CGCGAATTCGCG), Nucleic Acids Res., 16(6):2671-2690 (1988).
Martin et al, DNA Damage by Auger Emitters, Taylor & Francis, pp. 55-68 (1988).
Martin et al, Rapid Communication, Radiation Sensitization by an Iodine-labelled DNA Ligand, Int. J. Radiat. Biol., 57(5):939-946 (1990).
Martin et al, DNA: A Molecular Framework for Studying Reactive Species, Recueil des Travaux Chimiques des Pays-Bas, 106:178 (1987).
Martin et al, Preparation of Carrier Free[.sup.125 I]IodoHoechst 33258, Int. J. Appl. Radiat. Isot., 36(9):745-747 (1985).
Martin et al, Use of an .sup.125 I-labelled DNA Ligand to Probe DNA Structure, Nature, 302(5907):452-454 (1983).
Martin et al, Synthesis and N.M.R. Spectra of Substituted Aminoiodoacridines, Aust. J. Chem., 32:2637-2646 (1979).
Martin et al, Cytotoxicity of an .sup.125 I-labelled DNA-binding Compound that Induces Double-Stranded DNA Breaks, Cancer Res., 39:3244-3247 (1979).
Martin, Induction of Double-Stranded Breaks in DNA by Binding with an .sup.125 I-labelled Acridine, Int. J. Radiat. Biol., 32(5):491-497 (1977).
Martin et al, Synthesis and Characterization of 2-Iodo-4-[5"-(4'"-methylpiperazin-1'"-yl)-2",5'-bi-1H-benzimidazol-2'-yl]p henol (iodoHoechst 33258) and 2,5-Disubstituted Benzimidazole Model Compounds, Aust. J. Chem., 39:373-381 (1986).
Rodriguez et al, Continuous Infusion of Halogenated Pyrimidines, I. J. Radiation Oncology, Biology, Phsics, 20(6):1380-1381 (1991).
Ridley et al, A New Synthesis of Benzimidazoles and Aza-analogs, J. Het. Chem., 2:453-456 (1965).
Martin et al, Comparative Studies of UV-induced DNA Cleavage by Structural Isomers of an Iodinated DNA Ligand, Int. J. Radiat. Oncol. Biol. Phys. (in press) (1993).
Loewe et al, Basic-Substituted 2,6-Bisbenzimidazole Derivatives, a Novel Series of Substances with Chemotherapeutic Activity, J. Arzneim.-Forsch. (Drug Res.), 24:1927-1933 (1974) (with transl.).
Murray et al, The Degree of Ultraviolet Light Damage to DNA Containing Iododeoxyuridine or Bromodeoxyuridine is Dependent on the DNA Sequence, Nucleic Acids Res., 17(7):2675-2691 (1989).
Adams et al, Structure-Activity Relationships in the Development of Hypoxic Cell Radiosensitizers, Int. J. Radiat. Biol., 35(2):133-150 (1979).
Brown, Clinical Trails of Radiosensitizers: What Should We Expect?, Int. Radiat. Oncol. Biol. Phys., 10:425-429 (1984).
Martin et al. Chem. Abstr. No. 106:32923b, p. 539, 1987; Aus. J. Chem. 39(2):373-381, 1986.
Sano et al. Chem. Abstr. No. 70:6805, p. 672, 1969; No to Shinkei, 19:339-344, 1967.
Smith et al. Chem. Abstr. 102:92205w, p. 269, 1985; Int. J. Radiation Biol. Relat. Stud. Phys. Chem. Med. 46(4): 331-334, 1984.
Martin et al. Chemical Abstracts 93:46379d, 1980, Aust. J. Chem. 32(12):2637-2646, 1979.
Murray et al. J. Mol. Biol. 201:437-442, 1988.

Affiliated with

Also associated with

Rating

Halogenated DNA ligand radiosensitizers for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Halogenated DNA ligand radiosensitizers for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halogenated DNA ligand radiosensitizers for cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-149234